

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128781 A1

(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 25/14 (2006.01)
C07D 471/04 (2006.01) A61P 25/28 (2006.01)
A61P 19/02 (2006.01) A61P 37/06 (2006.01)
A61P 19/06 (2006.01) A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2024/059705

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,235 14 December 2023 (14.12.2023) US

(71) Applicant: **MERCK SHARP & DOHME LLC** [US/US];
126 East Lincoln Avenue, Rahway, New Jersey 07065 (US).

(72) Inventors: **BRILL, Zachary G.**; 126 East Lincoln Avenue,
Rahway, New Jersey 07065 (US). **HAYES, Donna A. A. W.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065
(US). **LAM, Tom M.**; 126 East Lincoln Avenue, Rahway,
New Jersey 07065 (US). **MCCLYMONT, Kyle S.**; 126
East Lincoln Avenue, Rahway, New Jersey 07065 (US).
MATSUURA, Bryan S.; 126 East Lincoln Avenue, Rah-
way, New Jersey 07065 (US). **MERCHANT, Rohan Ra-
jiv**; 126 East Lincoln Avenue, Rahway, New Jersey 07065
(US). **NAIR, Anilkumar G.**; 126 East Lincoln Avenue,
Rahway, New Jersey 07065 (US). **QI, Ning**; 126 East Lin-
coln Avenue, Rahway, New Jersey 07065 (US).

(74) Agent: **LAKE, Julie, M.**; 126 East Lincoln Avenue, Rah-
way, New Jersey 07065 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: AZAINDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3



(57) Abstract: Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLRP3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.